A Phase 4 interventional study of Optimal hypoglycemic treatment in Type2 Diabetes, sponsored by Nanjing First Hospital, Nanjing Medical University. Status unknown. Per ClinicalTrials.gov, last updated 2018-09-06.
Sponsored by Nanjing First Hospital, Nanjing Medical University · Phase 4, Interventional, and Treatment
Glargine is commonly used in insulin supplemental therapy in patients with type 2 diabetes(T2D) at present. However, many patients who treated with glargine still have poor blood glucose control because of insufficient insulin dose or improper oral medication. This study aims to investigate the optimal treatment scheme in order to improve the blood control in these patients. Continuous Glucose Monitoring System (CGMS) will be used to assess the blood glucose control at baseline and the moment when the patients achieved standard. Oral medications will be standardized first, and insulin doses will be adjusted according to blood glucose values obtained by self-monitoring. Glycemic control will be considered as reaching target of glucose if the fasting capillary blood glucose is less than 6.1 mmol/L. The maximum period of blood glucose adjustment will be 1 months. Oral medication, the type and dosage of insulin, exercise status, insulin injection skill evaluation, islet function, duration of diabetes, complications and insulin antibodies will be recorded in detail at baseline, reaching target of glucose standard and 3 months after reaching target of glucose.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 100 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Nanjing First Hospital, Nanjing Medical University is the lead sponsor of 213 studies on the registry; 106 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The patients will receive optimal hypoglycemic treatments, including adjustment of insulin dose and oral antidiabetic agents
Combination Product: Optimal hypoglycemic treatment
Standardize oral hypoglycemic medication and adjust insulin dose according to blood glucose values obtained by self-monitoring
Rate of reaching target of glucose
Rate of reaching target of glucose
Time frame: 0-1 month
HbA1c
Glycated hemoglobin at baseline and 3 months after reaching target of blood glucose
Time frame: 0-3 month
Dosage of insulin
Change of insulin dose
Time frame: 0-1 month
Time of reaching target of glucose
Time of reaching target of glucose
Time frame: 0-1 month
No study locations are listed for this record.
This study is status unknown, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanjing First Hospital, Nanjing Medical University